Question 1

What is congenital disorder of deglycosylation 1?

Accepted Answer

Congenital disorder of deglycosylation 1 is a rare multisystem condition caused by mutations in the NGLY1 gene. It primarily affects children, with developmental challenges and other neurological issues manifesting early in life. The condition is inherited in an autosomal recessive manner and is very rare, affecting fewer than 1 in 1 million people. Advances in supportive care have improved outcomes, although the course remains variable.

Question 2

What are the symptoms of congenital disorder of deglycosylation 1?

Accepted Answer

Individuals with congenital disorder of deglycosylation 1 typically present with a range of neurological and systemic symptoms. Characteristic features include persistent hypotonia, global developmental delay, and intellectual disability. After a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired skills, followed by variable stabilization or further decline. In addition, affected children often exhibit abnormal involuntary movements, seizures, poor tear production, and difficulties with oral-pharyngeal swallowing. Other clinical features such as microcephaly, distinctive excretion patterns in urine, and liver abnormalities contribute to the complex multisystem presentation. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes congenital disorder of deglycosylation 1?

Accepted Answer

This condition is caused by mutations in the NGLY1 gene, which encodes an enzyme critical for the deglycosylation process. It follows an autosomal recessive inheritance pattern, meaning that an affected individual inherits two copies of the mutated gene, one from each parent. The condition is more common when parents share a common ancestor, increasing the likelihood that both carry the same rare genetic variant. Families are encouraged to seek genetic counseling to better understand recurrence risks and to discuss family planning options. Associated genes include NGLY1.

Question 4

How is congenital disorder of deglycosylation 1 inherited?

Accepted Answer

congenital disorder of deglycosylation 1 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is congenital disorder of deglycosylation 1?

Accepted Answer

congenital disorder of deglycosylation 1 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is congenital disorder of deglycosylation 1 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the NGLY1 gene. Clinical evaluation, which includes assessment of developmental history, neurological examinations, and observation of characteristic features such as hypotonia and abnormal movements, supports the diagnostic process. Although specific biochemical or imaging biomarkers have been noted, genetic testing remains the gold standard for definitive diagnosis. Because many of these features can overlap with other conditions, an accurate diagnosis relies on confirming the genetic basis of the disorder.

Question 7

Are there treatments for congenital disorder of deglycosylation 1?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as there are no FDA-approved treatments specifically for congenital disorder of deglycosylation 1. Treatment is tailored to each individual and typically involves a multidisciplinary team approach, including regular surveillance and monitoring to address both neurological and systemic issues. Supportive therapies may include physical and occupational therapy, and genetic counseling is recommended to help families understand the condition and explore management strategies. Patients should discuss treatment options with their healthcare team to determine which therapies are most appropriate for their situation.

Question 8

Are there clinical trials for congenital disorder of deglycosylation 1?

Accepted Answer

Yes, there is currently 1 active clinical trial for congenital disorder of deglycosylation 1 registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 9

Where can I find support for congenital disorder of deglycosylation 1?

Accepted Answer

Patient advocacy organizations for congenital disorder of deglycosylation 1 include Grace Science Foundation. These organizations can provide information, connect you with other families, and help navigate care. Visit the Support section of this page for full details and contact information.

Question 10

What are the long-term effects of congenital disorder of deglycosylation 1 on development?

Accepted Answer

Congenital disorder of deglycosylation 1 can lead to lifelong developmental challenges. Many children experience an initial regression in skills after early development, followed by a period of stabilization or further decline. The long-term effects vary widely among individuals, depending on the severity of symptoms and access to care.

Question 11

How does congenital disorder of deglycosylation 1 affect daily life for children?

Accepted Answer

Children with congenital disorder of deglycosylation 1 may face challenges in daily activities due to symptoms like hypotonia and difficulties with swallowing. Supportive therapies, such as physical and occupational therapy, can help improve their abilities. Families often need to adapt their routines to provide the necessary support and care.

Question 12

What is the prognosis for individuals with congenital disorder of deglycosylation 1?

Accepted Answer

The prognosis for congenital disorder of deglycosylation 1 varies greatly among individuals. Some may experience improvements in quality of life with current standards of care, while others may face ongoing challenges. Regular monitoring and access to specialized care can help manage symptoms and support development over time.

Organ System	Phenotype Count	Example Features
Brain and nerves	20	Action tremor, High myoinositol in brain by MRS, Seizure
Eyes	4	Cloudy or opaque cornea (corneal opacity), Strabismus, Corneal ulceration
Digestive system	4	Liver scarring (fibrosis) (hepatic fibrosis), Enlarged liver (hepatomegaly), Elevated circulating hepatic transaminase concentration
Arms and legs	3	Short foot, Intrinsic hand muscle atrophy, Small hand
Muscles	3	Low muscle tone (hypotonia), Facial hypotonia, Intrinsic hand muscle atrophy
Head and neck	3	Facial hypotonia, Microcephaly, Narrow face
Lab test results	3	Increased circulating lactate concentration, Elevated circulating alpha-fetoprotein concentration, Elevated circulating hepatic transaminase concentration
Lungs and breathing	3	Respiratory distress, Central sleep apnea, Recurrent respiratory infections
Skin	2	Anhidrosis, Excessive sweating (hyperhidrosis)
Bones and joints	2	Weak and brittle bones (osteoporosis), Sideways curvature of the spine (scoliosis)
Metabolism	1	Fever
Blood and immune system	1	Recurrent respiratory infections

System/Concern	Evaluation	Comment
Eyes	Ophthalmologic eval for hypolacrima retinal disease	—
ENT/Mouth	Auditory brain stem evoked potentials	—

Research Type	Count	% of Total
Laboratory research	10	37%
Research summaries	6	22%
Disease patterns and progression	3	11%
Testing and diagnosis research	2	7%
Patient case studies	2	7%
New treatment approaches	2	7%
Other research	1	4%
Clinical study results	1	4%

Kisho

congenital disorder of deglycosylation 1

Overview

Clinical Presentation

Clinical Guidance

Explore clinical features

Genetic Landscape

Diagnosis

Diagnostic Criteria

Suggestive Findings

Establishing the Diagnosis

Differential Diagnosis

Treatment

Orphan Drug Designations

Management Guidelines

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Patient Support

Patient Advocacy Groups

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

congenital disorder of deglycosylation 1

Overview

Clinical Presentation

Clinical Guidance

Explore clinical features

Genetic Landscape

Diagnosis

Diagnostic Criteria

Suggestive Findings

Establishing the Diagnosis

Differential Diagnosis

Treatment

Orphan Drug Designations

Management Guidelines

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Patient Support

Patient Advocacy Groups

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is congenital disorder of deglycosylation 1?

What are the symptoms of congenital disorder of deglycosylation 1?

What causes congenital disorder of deglycosylation 1?

How is congenital disorder of deglycosylation 1 inherited?

How rare is congenital disorder of deglycosylation 1?

How is congenital disorder of deglycosylation 1 diagnosed?

Are there treatments for congenital disorder of deglycosylation 1?

Are there clinical trials for congenital disorder of deglycosylation 1?

Where can I find support for congenital disorder of deglycosylation 1?

What are the long-term effects of congenital disorder of deglycosylation 1 on development?

How does congenital disorder of deglycosylation 1 affect daily life for children?

What is the prognosis for individuals with congenital disorder of deglycosylation 1?